Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16581324 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL126543 | 0.82 | HDAC3 (0.34) | TSHRMETAP2HDAC3HDAC4HDAC1 | |
| SCHEMBL12285898 | 0.79 | TSHR (0.52) | ALDH1A1TSHRMETAP2TDP1HTT | |
| SCHEMBL25923045 | 0.78 | NAAA (0.45) | ALDH1A1GAALMNAMETAP2HTT | |
| SCHEMBL12285540 | 0.77 | TSHR (0.53) | ALDH1A1TSHRSMN1; SMN2HSD17B10METAP2 | |
| SCHEMBL25755665 | 0.77 | MMP1 (0.37) | ALDH1A1TSHRMETAP2TDP1 | |
| SCHEMBL17253261 | 0.75 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL11652510 | 0.75 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL10665153 | 0.75 | METAP2 (0.32) | TSHRMETAP2 | |
| SCHEMBL1104791 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130029909-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2013-01-31 | — | — | US | disclosed |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120114658-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120064071-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110282047-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110160159-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114658-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885CHRM5 4196/4885CHRM1 4598/4885 |
| US-20130029909-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | DDOST, SDCBP, STT3B | ALDH1A1 2405/4885CHRM5 4130/4885CHRM1 4492/4885 |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | CD47, SDCBP, BST2 | ALDH1A1 2837/4885CHRM5 2546/4885CHRM1 3556/4885 |
| US-20120064071-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 2646/4885CHRM5 3170/4885CHRM1 4112/4885 |
| US-20110160159-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | ALDH1A1 3058/4885CHRM5 2560/4885CHRM1 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.